Otsuka to acquire Transcend therapeutics in up to $1.225bn neuroscience deal

Otsuka Pharmaceutical has agreed to acquire clinical-stage biotech Transcend Therapeutics for $700 million upfront, plus up to $525 million in milestones. The deal centers on TSND-201, a non-hallucinogenic neuroplastogen in Phase 3 development for post-traumatic stress disorder (PTSD).

Otsuka Pharmaceutical, through its subsidiary Otsuka America, will acquire Transcend Therapeutics in a transaction valued at up to $1.225 billion. The agreement includes an upfront payment of $700 million upon closing, expected in the second quarter of 2026, with additional contingent consideration of up to $525 million tied to future sales milestones. Transcend, a clinical-stage biotechnology company founded in 2021, develops rapid-acting treatments for neuropsychiatric diseases.

The acquisition centers on TSND-201 (methylone), a Phase 3 asset for PTSD that received Breakthrough Therapy designation from the FDA in July 2025. Unlike conventional psychedelic compounds, TSND-201 acts on monoamine transporters without activating the serotonin 5-HT2A receptor, positioning it as a non-hallucinogenic neuroplastogen that promotes rapid neural plasticity. Positive Phase 2 results were published in JAMA Psychiatry in February 2026.

For Otsuka, the acquisition addresses a significant unmet need in psychiatry. An estimated 13 million individuals in the U.S. are affected by PTSD annually, with no new treatments approved in 25 years. The transaction expands Otsuka’s neuroscience portfolio beyond its established antipsychotics and antidepressants into next-generation neuroplasticity-based therapies.

Otsuka Pharmaceutical is a global healthcare company headquartered in Tokyo, with longstanding focus on psychiatric and neurological disorders.

Transcend Therapeutics is a New York-based clinical-stage biotech developing rapid-acting neuroplastogens for neuropsychiatric conditions.